论文部分内容阅读
目的观察HG/HAG方案治疗骨髓增生异常综合征(MDS-RAEB)的临床效果。方法MDS初治患者23例,经骨髓细胞形态学、免疫学等检查确诊为MDS-RAEB。HG方案:HHT0.5～1.0mg/(d.m2),静滴,连用10～14d,G-CSF150～300μg皮下注射,1次/d,连用10～14d;HAG方案:HG方案基础上加用Ara-c10～20mg/(d.m2),静滴,连用10～14d。连用2个疗程,观察其疗效和不良反应等。结果11例(47.8%)完全缓解,6例(26.1%)部分缓解,有效率为73.9%,不良反应较轻,无一例早期死亡。结论HG/HAG方案对MDS-RAEB疗效较好,不良反应小。
Objective To observe the clinical effect of HG / HAG regimen in the treatment of myelodysplastic syndrome (MDS-RAEB). Methods Twenty-three newly diagnosed MDS patients were diagnosed as MDS-RAEB by morphology, immunology and other tests. HG program: HHT 0.5 ~ 1.0mg / (d.m2), intravenous infusion, once every 10 ~ 14d, G-CSF 150 ~ 300μg subcutaneously, once / d, once every 10 ~ 14d; With Ara-c10 ~ 20mg / (d.m2), intravenous infusion, once every 10 ~ 14d. Used two courses, observe its efficacy and adverse reactions. Results 11 cases (47.8%) were completely relieved, and 6 cases (26.1%) were partially relieved. The effective rate was 73.9%. The adverse reaction was mild and none of them died early. Conclusions HG / HAG regimen has good curative effect on MDS-RAEB with small adverse reaction.